• MDxHealth SA MDXH.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of five analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -30 cents to -25 cents per share.

• Revenue rose 20.5% to $23.32 million from a year ago; analysts expected $21.48 million.

• MDxHealth SA's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $11.19 million.

• MDxHealth SA shares had fallen by 0.5% this quarter and lost 47.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for MDxHealth SA is 7.00

This summary was machine generated from LSEG data November 7 at 04:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)